ARTICLE
4 December 2024

Key Takeaways | State Of The Market – Still Looking For An Exit

MW
McDermott Will & Emery

Contributor

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With more than 1,100 lawyers across several office locations worldwide, our team works seamlessly across practices, industries and geographies to deliver highly effective solutions that propel success.
During this session, the panelists discussed notable developments within the life sciences industry with a specific focus on the GLP-1 drug market and its opportunities for improvement in patient satisfaction and dosage.
United States Food, Drugs, Healthcare, Life Sciences

During this session, the panelists discussed notable developments within the life sciences industry with a specific focus on the GLP-1 drug market and its opportunities for improvement in patient satisfaction and dosage. They also focused on recent increased deal activity and creativity within the MedTech industry while monitoring mid-tier deals in other areas of biopharma.

Session panelists:

  • Rick Aldridge, Managing Director, Healthcare M&A, Lazard
  • Ellen Baron, Managing Director, Outcome Capital
  • Dennis Crowley, Vice President, Solventum
  • Nicholas Downing, MD, Managing Director, Life Sciences, Bain Capital
  • Jimmy Zhuang, Assistant General Counsel, Novo Nordisk
  • Moderator: Byron Kalogerou, Partner, McDermott Will & Emery

In Depth

Top takeaways included:

  • Innovation Is Not Cyclical. Even though markets may come and go, the life sciences industry always maintains a steady stream of creative ideas. Despite other market fluctuations, life sciences consistently enters new marketplaces, such as investments in weight loss drugs, marking the "GLP-1 era."
  • Consider Investing in the GLP-1 Market. When determining what product or service to develop or whether to invest, consider current notable developments within the GLP-1 drug market. GLP-1 medications are used to treat diabetes and obesity and are relied upon in numerous medical fields. Notably, the GLP-1 market is accompanied by a large venture capital investor backing. Despite the quickening pace of the GLP-1 market, however, competitors are vying for venture funds on a global scale. Future venture funding may focus on GLP-1 developments that align with patient feedback and remedy potential side effects. For example, an overview of current GLP-1 patient satisfaction indicates patients desire a reduction in dosage of GLP-1 injections at less frequency.
  • Stay Updated on Market Developments Within Biopharma. In comparison to 2023, there is accelerated dealmaking activity in the mergers and acquisitions (M&A) life sciences sector. Notwithstanding increased deal activity, 2024 deals have been mid-tier with less money and without any major-tier acquisitions. The MedTech field, however, has experienced greater M&A and venture capital activity with more financing and major-tier acquisitions.
  • Buyers Discover Good Business When the Time Is Right. Deals are opportunistic. Therefore, the challenge becomes how to discern what creates value in the long term. Although a buyer exiting a deal may initially experience disappointment, it can also open opportunities for continued relationships.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More